Making Methotrexate More Effective Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p

• Making Methotrexate More Effective | RheumNow

SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

• SLE Pipeline of New Therapies | RheumNow

Treat to Target Works in Elderly Onset RA Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP

• Treat to Target Works in Elderly Onset RA | RheumNow

Digital Platforms and AI Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions. https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf

• Digital Platforms and AI | RheumNow

Digital Patient Education in RA Dr. Bella Mehta reviews abstract OP005-HPR presented in London at EULAR 2026 https://t.co/Wj8omKJTNx. https://t.co/h13p54BAHs

• Digital Patient Education in RA | RheumNow

Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f

All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.

Day 1 Report from EULAR 2026 The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat

The pain that inflammation does not explain in SpA and PsA At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1

#TYK2i #deucravacitinib #RCT in #SLE LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts #POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9

• https://x.com/Janetbirdope/status/2063550807128023145/photo/1

Who does better in active #RA b/tsDMARD naive? Pt choice TNFi or JAKi OR Pt randomized to TNFI or JAKi? Strangely or not PT choice did better ✅with satisfaction ~maybe expected ✅better retention on chosen #Rx 🤔unexpected another arm in #RCTS?” #EULAR2026 @RheumNow OP0204 https://t.co/7qx5Rqq6a7

• https://x.com/Janetbirdope/status/2063541514844697071/photo/1
• https://x.com/Janetbirdope/status/2063541514844697071/photo/1
• https://x.com/Janetbirdope/status/2063541514844697071/photo/1